INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “
Separately, Leerink Swann restated a “buy” rating on shares of INNATE PHARMA EUR0.05 in a research note on Wednesday, August 17th.
INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) traded up 2.11% during mid-day trading on Wednesday, reaching $15.00. 1,350 shares of the company were exchanged. The company’s 50 day moving average price is $12.86 and its 200-day moving average price is $12.54. The stock’s market capitalization is $808.16 million. INNATE PHARMA EUR0.05 has a 12-month low of $10.36 and a 12-month high of $16.00.